Author： Oberstein Paul E. Hershman Dawn L.
Publisher： Informa Healthcare
ISSN： 0735-7907
Source： Cancer Investigation, Vol.31, Iss.5, 2013-06, pp. : 316-322
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Gemcitabine was approved for advanced pancreatic cancer in 1996. We investigated uptake and predictors of its use. We identified 3,231 individuals > 65 years in the SEER-Medicare database with stage IV pancreatic adenocarcinoma, diagnosed between 1998-2005, who survived >30 days. Of these, 54% received chemotherapy, 93% with gemcitabine. Gemcitabine nonreceipt was associated with advanced age and unmarried (OR: 0.65, 95% CI: 0.55-0.76). Diagnosis in 2004-2005 versus 1998-2000 was more likely to receive gemcitabine (OR: 1.51, 95% CI: 1.23-1.84) as were higher SES patients (highest versus lowest quintile, OR: 2.14, 95% CI: 1.60-2.85). Gemcitabine was rapidly adopted among elderly advanced pancreatic cancer patients; several factors are associated with use.
Related content
Access to resources
Recommend
By Ko Andrew Dito Elizabeth Schillinger Brian Venook Alan Bergsland Emily Tempero Margaret
Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. :
By Song Hong Do Young Chang Heung Ryu Min Lee Kyung Kim Yeul Hong Dae Cho Jae Lee Kyoung Kim Si
Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. :
By Ko Andrew Venook Alan Bergsland Emily Kelley R. Korn W. Dito Elizabeth Schillinger Brian Scott Janet Hwang Jimmy Tempero Margaret
Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. :